CTOs on the Move

Ocular Therapeutix

www.ocutx.com

 
Founded in 2006, Ocular Therapeutix is a fast-growing, aspiring leader in the biopharmaceutical industry. The company has a clear vision – to improve current therapeutic options in ophthalmology by encapsulating previously approved therapeutic agents in our novel hydrogel to provide a sustained delivery of drugs to the eye. We are reframing the industry with new modalities for ophthalmic therapies. As a small company, our employees are provided the unique opportunity to help build the foundation of the business as it grows. We strongly believe that our success is contingent upon the achievements of our employees. We strive to create a ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ocutx.com
  • 34 Crosby Drive Ste 105
    Bedford, MA USA 01730
  • Phone: 781.357.4000

Executives

Name Title Contact Details
Steve Fedan
Director of Information Technology Profile

Funding

Ocular Therapeutix raised $35.1M on 01/30/2018

Similar Companies

MicroCal

MicroCal, LLC is a Northampton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kernel Co

Kernel is a human intelligence (HI) company. We`re a team of scientists and engineers on a mission to dramatically increase our quality of life and create a thriving humanity. We believe that starts with a renewed focus on human intelligence (HI). Machines of all kinds can help us along the way, but our vision is one in which we humans maintain and expand our authorial power. The advanced intelligence of tomorrow is a collaboration between the natural and the artificial. United, unheard of possibilities abound. We`re building off two decades of breakthrough research, working closely with private partners and scientists to get usable solutions in the hands of people everywhere. We’re starting with potential applications for patients with cognitive disorders.

Ulthera

Ulthera is a Mesa, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Modulim

Modulim is a pioneer in optical imaging solutions powered by spatial frequency domain imaging (SFDI) for noninvasive tissue and vascular assessment. Powered by SFDI, our Clarifi® Imaging System helps clinicians identify patients at-risk of complications due to microvascular dysfunction. The #ClarifiImagingSystem quantifies and maps five biomarkers of microvascular tissue oxygenation and perfusion. As a result, clinicians can quickly identify at-risk patients for earlier and more timely intervention so they may prevent complications such as diabetic foot ulcers and amputations. With its widespread adoption, our technology solutions have the potential to save limbs and lives, improve outcomes and reduce costs across the continuum of care by enabling early detection and intervention. Clarifi is affordable and easily integrated into a clinician`s practice. Clarifi imaging is supported by reimbursement (Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code (0061U). Our proprietary technology - SFDI - was invented by Modulim`s founder and CTO David Cuccia, Ph.D., and his colleagues at UC Irvine`s Beckman Laser Institute. SFDI is a noninvasive tissue oxygen saturation technology that combines structured illumination with multiple wavelengths of light (visible and near-infrared) to allow for deeper and layer-specific assessment of tissue oxygenation and hemoglobin. This unique technology deciphers the reflection, absorbance, and scattering of light in tissue. Both David and Amaan Mazhar, Ph.D., Modulim`s VP of Research & Development, are both internationally-recognized experts in the field of medical photonics. #seebeyond

iCAD

With iCAD`s technology, cancer has finally met its match. As a global medical technology leader providing innovative cancer detection and therapy solutions, our technologies empower clinicians worldwide with an arsenal of tools to detect cancer and stop it in its tracks – streamlining workflow, improving accuracy, and personalizing results like never before. The ProFound AI Breast Health Suite is the first, best, and only complete, triple-threat solution that combines cancer detection, density assessment, and risk evaluation – all designed to accelerate discovery and improve outcomes. Our leading-edge cancer detection solution, ProFound AI®, is clinically proven to find cancers earlier and with greater accuracy, while slashing reading time for radiologists by more than half. PowerLook® Density Assessment simplifies and standardizes breast density reporting and stratification, offering consistent, accurate and reliable breast density categorization. And the latest addition to our Breast AI Suite, ProFound AI® Risk, is the world`s first clinical decision support tool that provides an accurate short-term breast cancer risk estimation that is truly personalized for each woman, based only on her mammogram. Our Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is transforming the cancer treatment experience by empowering physicians to precisely and effectively target tumors anywhere in the body, anywhere in the world. Using the world`s smallest X-ray source, clinicians can precisely destroy disease while preserving healthy tissue, leaving cancer nowhere to hide.